Mesothelin Targeted Cancer Immunotherapy

Overview

Journal Eur J Cancer

Specialty Oncology

Date 2007 Oct 20

PMID 17945478

Citations 169

Authors

Raffit Hassan

Mitchell Ho

Affiliations

Soon will be listed here.

Abstract

Mesothelin is a tumour differentiation antigen that is normally present on the mesothelial cells lining the pleura, peritoneum and pericardium. It is, however, highly expressed in several human cancers including malignant mesothelioma, pancreatic, ovarian and lung adenocarcinoma. The normal biologic function of mesothelin is unknown but recent studies have shown that it binds to CA-125 and may play a role in the peritoneal spread of ovarian cancer. The limited mesothelin expression in normal tissues and high expression in many cancers makes it an attractive candidate for cancer therapy. Three mesothelin targeted agents are in various stages of clinical evaluation in patients. These include SS1P (CAT-5001) a recombinant immunotoxin targeting mesothelin, MORAb-009 a chimeric anti-mesothelin monoclonal antibody and CRS-207 a live-attenuated Listeria monocytogenes vector encoding human mesothelin. These ongoing clinical trials will help define the utility of mesothelin as a target for cancer therapy.

Citing Articles

Targeting mesothelin-CD24 axis repolarizes tumor-associated macrophages to potentiate PD-1 blockade therapy in high-grade serous ovarian cancer.

Zhong Y, Wang Y, Wang C, Cao K, Wang X, Xu X J Immunother Cancer. 2025; 13(2).

PMID: 40010770 PMC: 11873354. DOI: 10.1136/jitc-2024-011230.

Characterization of mesothelin gene expression in dogs and overexpression in canine mesotheliomas.

Nabeta R, Kanaya A, Shimada K, Matsuura K, Yoshimura A, Oyamada T Front Vet Sci. 2024; 11:1436621.

PMID: 39315086 PMC: 11417096. DOI: 10.3389/fvets.2024.1436621.

Immunotherapy for small cell lung cancer: the current state and future trajectories.

Qiang M, Liu H, Yang L, Wang H, Guo R Discov Oncol. 2024; 15(1):355.

PMID: 39152301 PMC: 11329494. DOI: 10.1007/s12672-024-01119-5.

Targeted Therapy in Mesotheliomas: Uphill All the Way.

Bertoli E, De Carlo E, Bortolot M, Stanzione B, Del Conte A, Spina M Cancers (Basel). 2024; 16(11).

PMID: 38893092 PMC: 11171080. DOI: 10.3390/cancers16111971.

Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from TC2N.

Yang Z, Zhang H, Xia X, Zhang J Eur J Microbiol Immunol (Bp). 2024; 14(1):59-65.

PMID: 38358441 PMC: 10895358. DOI: 10.1556/1886.2024.00002.

References

Gubbels J, Belisle J, Onda M, Rancourt C, Migneault M, Ho M . Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006; 5(1):50. PMC: 1635730. DOI: 10.1186/1476-4598-5-50. View

Brockstedt D, Giedlin M, Leong M, Bahjat K, Gao Y, Luckett W . Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A. 2004; 101(38):13832-7. PMC: 518841. DOI: 10.1073/pnas.0406035101. View

Chowdhury P, Viner J, Beers R, Pastan I . Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci U S A. 1998; 95(2):669-74. PMC: 18478. DOI: 10.1073/pnas.95.2.669. View

Chowdhury P, Pastan I . Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotechnol. 1999; 17(6):568-72. DOI: 10.1038/9872. View

Frierson Jr H, Moskaluk C, Powell S, Zhang H, Cerilli L, Stoler M . Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol. 2003; 34(6):605-9. DOI: 10.1016/s0046-8177(03)00177-1. View

Hassan R, Laszik Z, Lerner M, Raffeld M, Postier R, Brackett D . Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol. 2006; 124(6):838-45. View

Hassan R, Bera T, Pastan I . Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004; 10(12 Pt 1):3937-42. DOI: 10.1158/1078-0432.CCR-03-0801. View

Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M . Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2003; 279(10):9190-8. DOI: 10.1074/jbc.M312372200. View

Prieve M, Moon R . Stromelysin-1 and mesothelin are differentially regulated by Wnt-5a and Wnt-1 in C57mg mouse mammary epithelial cells. BMC Dev Biol. 2003; 3:2. PMC: 155645. DOI: 10.1186/1471-213x-3-2. View

10.

Chang K, Pastan I, Willingham M . Frequent expression of the tumor antigen CAK1 in squamous-cell carcinomas. Int J Cancer. 1992; 51(4):548-54. DOI: 10.1002/ijc.2910510408. View

11.

Yokokawa J, Palena C, Arlen P, Hassan R, Ho M, Pastan I . Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin Cancer Res. 2005; 11(17):6342-51. PMC: 1351144. DOI: 10.1158/1078-0432.CCR-05-0596. View

12.

Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz R . Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001; 7(12):3862-8. View

13.

Pastan I, Hassan R, Fitzgerald D, Kreitman R . Immunotoxin therapy of cancer. Nat Rev Cancer. 2006; 6(7):559-65. DOI: 10.1038/nrc1891. View

14.

Yen M, Hsu C, Mao T, Wu T, Roden R, Wang T . Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res. 2006; 12(3 Pt 1):827-31. DOI: 10.1158/1078-0432.CCR-05-1397. View

15.

Bera T, Pastan I . Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol. 2000; 20(8):2902-6. PMC: 85523. DOI: 10.1128/MCB.20.8.2902-2906.2000. View

16.

Ho M, Bera T, Willingham M, Onda M, Hassan R, Fitzgerald D . Mesothelin expression in human lung cancer. Clin Cancer Res. 2007; 13(5):1571-5. DOI: 10.1158/1078-0432.CCR-06-2161. View

17.

Chang K, Pastan I . Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A. 1996; 93(1):136-40. PMC: 40193. DOI: 10.1073/pnas.93.1.136. View

18.

Miettinen M, Sarlomo-Rikala M . Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol. 2003; 27(2):150-8. DOI: 10.1097/00000478-200302000-00002. View

19.

Jaffee E, Hruban R, Biedrzycki B, Laheru D, Schepers K, Sauter P . Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 2001; 19(1):145-56. DOI: 10.1200/JCO.2001.19.1.145. View

20.

Chang K, Pai L, Pass H, Pogrebniak H, Tsao M, Pastan I . Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol. 1992; 16(3):259-68. DOI: 10.1097/00000478-199203000-00006. View